House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices. “We’re working between the Commerce Committee and the Judiciary Committee on a compromise on what we call CREATES, which is getting the generics online faster after patents have expired, so I think there are things we can do in that area,” Ryan said, according to published reports, during an event hosted by a Washington, D.C. law firm. Among other provisions, the legislation would allow a generic drug manufacturer facing a sample-sharing delay tactic to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Earlier this year, AHA and more than 40 organizations urged Congress to pass the legislation calling it “a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year.”

Related News Articles

Headline
he House of Representatives last night voted 234-183 to pass legislation (H.R. 987) that combines several AHA-supported bills to help lower prescription drug…
Headline
The Centers for Medicare…
Headline
Sens. Bill Cassidy, R-La., Michael Bennet, D-Colo., Todd Young, R-Ind., Maggie Hassan, D-N.H., Lisa Murkowski, R-Alaska, and Tom Carper, D-Del., today…
Blog
Drug companies are at it again. And their latest effort to divert the focus from the huge profits they pocket as drug prices rise is just as disingenuous as…
Headline
House Energy and Commerce Committee leaders today released a discussion draft of bipartisan legislation to address surprise medical bills.
Headline
The largest U.S. pharmaceutical and biotech companies spend just 22 cents out of every dollar on research and development, according to an analysis released…